IVEVF Articles, Inventiva SA

Daix, 21 June 2024  Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l'Autorité des marchés financiers), ...

Daix (France), Long Island City (New York, United States), May 30, 2024 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company foc...

The first abstract demonstrates that the improvements of MACK-3, a diagnostic test for metabolic dysfunction-associated steatohepatitis, parallel...

Cash and cash equivalents at €11.0 million, short-term2 deposits at €0.1million, and long-term deposit at €19.1 million3 as of March 31, 20...

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned r...

Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), ...

Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceu...

Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmace...

Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022  Cash and cash equivalents at €26.9 millio...

Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company f...